Zetia, a cholesterol-reducing drug, marketed by Merck and Shering Plough, has recently come under scrutiny by the House Committee on Energy and Commerce. The House is investigating the results of a recent clinical trial of Zetia. This clinical trial was designed to confirm Zetia’s ability to reduce the growth of plaque in arteries when combined with another cholesterol drug. Although the clinical trial was conducted in April 2006, the results have yet been released. To read more about this article visit: http://www.nytimes.com/2007/12/12/business/12zetia.html?_r=l&ref=health&oref=slogin
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.